<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Tissue plasminogen activator (tPA) is the only approved therapy for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, tPA has a brief therapeutic window </plain></SENT>
<SENT sid="2" pm="."><plain>Its side effects include <z:mp ids='MP_0001916'>intracerebral bleeding</z:mp> and neurotoxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, a combination therapy with tPA and agents that can extend the therapeutic window of tPA and/or counteract its side effects are warranted </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we studied whether 3K3A-APC, a neuroprotective analog of activated protein C with reduced <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity, can enhance the therapeutic effects of tPA in models of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in rodents </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: Human recombinant tPA (10 mg/kg), alone or in combination with human recombinant 3K3A-APC (2 mg/kg), was administered intravenously 4 hours after proximal or distal transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice and embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> in rats </plain></SENT>
<SENT sid="6" pm="."><plain>The 3K3A-APC was additionally administered for 3 to 4 consecutive days after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The neuropathological and neurological analyses were performed at 1 to 7 days after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In <z:hpo ids='HP_0000001'>all</z:hpo> models, tPA alone had no effects on the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume or behavior (ie, neurological score, foot-fault, forelimb asymmetry, adhesive removal) compared with vehicle </plain></SENT>
<SENT sid="9" pm="."><plain>The tPA and 3K3A-APC combination therapy reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 24 hours and 7 days after proximal or distal transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice and 7 days after embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> in rats by 65%, 63%, and 52%, respectively, significantly (P&lt;0.05) improved behavior and eliminated tPA-induced intracerebral microhemorrhages </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The 3K3A-APC extends the therapeutic window of tPA for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in rodents </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, this combination therapy also should be considered for treating <z:hpo ids='HP_0001297'>stroke</z:hpo> in humans </plain></SENT>
</text></document>